Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Am J Physiol Heart Circ Physiol. 2013 Oct 1;305(7):H1104-10. doi: 10.1152/ajpheart.00447.2013. Epub 2013 Jul 19.
The objective of this study was to compare heart-specific fatty acid binding protein (hFABP) and high-sensitivity troponin I (hsTnI) via serial measurements to identify early time points to accurately quantify infarct size and no-reflow in a preclinical swine model of ST-elevated myocardial infarction (STEMI). Myocardial necrosis, usually confirmed by hsTnI or TnT, takes several hours of ischemia before plasma levels rise in the absence of reperfusion. We evaluated the fast marker hFABP compared with hsTnI to estimate infarct size and no-reflow upon reperfused (2 h occlusion) and nonreperfused (8 h occlusion) STEMI in swine. In STEMI (n = 4) and STEMI + reperfusion (n = 8) induced in swine, serial blood samples were taken for hFABP and hsTnI and compared with triphenyl tetrazolium chloride and thioflavin-S staining for infarct size and no-reflow at the time of euthanasia. hFABP increased faster than hsTnI upon occlusion (82 ± 29 vs. 180 ± 73 min, P < 0.05) and increased immediately upon reperfusion while hsTnI release was delayed 16 ± 3 min (P < 0.05). Peak hFABP and hsTnI reperfusion values were reached at 30 ± 5 and 139 ± 21 min, respectively (P < 0.05). Infarct size (containing 84 ± 0.6% no-reflow) correlated well with area under the curve for hFABP (r(2) = 0.92) but less for hsTnI (r(2) = 0.53). At 50 and 60 min reperfusion, hFABP correlated best with infarct size (r(2) = 0.94 and 0.93) and no-reflow (r(2) = 0.96 and 0.94) and showed high sensitivity for myocardial necrosis (2.3 ± 0.6 and 0.4 ± 0.6 g). hFABP rises faster and correlates better with infarct size and no-reflow than hsTnI in STEMI + reperfusion when measured early after reperfusion. The highest sensitivity detecting myocardial necrosis, 0.4 ± 0.6 g at 60 min postreperfusion, provides an accurate and early measurement of infarct size and no-reflow.
本研究旨在通过连续测量心脏特异性脂肪酸结合蛋白(hFABP)和高敏肌钙蛋白 I(hsTnI),比较两者在经皮冠状动脉介入治疗(PCI)治疗前壁 ST 段抬高型心肌梗死(STEMI)患者中的作用,以识别能准确量化梗死面积和无复流的早期时间点。在无再灌注的情况下,心肌坏死通常在 hsTnI 或 TnT 确认的几小时缺血后血浆水平才会升高。我们评估了快速标志物 hFABP,与 hsTnI 相比,可在再灌注(2 小时闭塞)和非再灌注(8 小时闭塞)STEMI 猪模型中估计梗死面积和无复流。在 STEMI(n=4)和 STEMI+再灌注(n=8)诱导的猪中,连续采集血样,检测 hFABP 和 hsTnI,并在安乐死时用三苯基四唑氯(TTC)和硫代黄素 S(thioflavin-S)染色比较梗死面积和无复流。hFABP 在闭塞时比 hsTnI 更快地增加(82±29 与 180±73min,P<0.05),并在再灌注时立即增加,而 hsTnI 释放延迟 16±3min(P<0.05)。hsFABP 和 hsTnI 的再灌注峰值分别在 30±5min 和 139±21min 达到(P<0.05)。梗死面积(含 84±0.6%无复流)与 hFABP 的曲线下面积相关性良好(r(2)=0.92),但与 hsTnI 的相关性较差(r(2)=0.53)。在再灌注 50 和 60min 时,hFABP 与梗死面积(r(2)=0.94 和 0.93)和无复流(r(2)=0.96 和 0.94)相关性最好,并且对心肌坏死具有高灵敏度(2.3±0.6 和 0.4±0.6g)。hsFABP 在再灌注后早期测量时,比 hsTnI 更快地升高,与 STEMI+再灌注中的梗死面积和无复流相关性更好。再灌注后 60min 时检测心肌坏死的最高灵敏度为 0.4±0.6g,可准确、早期测量梗死面积和无复流。